Compass Therapeutics (NASDAQ:CMPX) Earns Outperform Rating from Wedbush

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “outperform” rating restated by Wedbush in a research note issued to investors on Tuesday,RTT News reports. They presently have a $8.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 373.37% from the stock’s current price.

A number of other analysts have also commented on the stock. Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target for the company. Guggenheim initiated coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They issued a “buy” rating and a $12.00 price target on the stock. D. Boral Capital reissued a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Jefferies Financial Group increased their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $11.63.

Compass Therapeutics Trading Down 24.6 %

CMPX opened at $1.69 on Tuesday. The company has a market cap of $233.70 million, a P/E ratio of -4.57 and a beta of 1.19. The company has a fifty day moving average price of $2.81 and a two-hundred day moving average price of $2.11. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers boosted its holdings in shares of Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after buying an additional 3,822 shares during the last quarter. Invesco Ltd. boosted its stake in Compass Therapeutics by 11.3% in the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock valued at $57,000 after acquiring an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Compass Therapeutics by 2.6% in the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Compass Therapeutics by 31.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock worth $69,000 after purchasing an additional 11,326 shares during the last quarter. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.